Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)
| Status: | Terminated |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 21 - 85 |
| Updated: | 4/21/2016 |
| Start Date: | November 2008 |
| End Date: | August 2014 |
Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After PCI
This research study plans to evaluate the use of atorvastatin in patients with coronary
artery disease given immediately before PCI and whether it will decrease the amount of heart
damage after PCI.
artery disease given immediately before PCI and whether it will decrease the amount of heart
damage after PCI.
Inclusion Criteria:
- patients undergoing revascularization for significant coronary artery disease
- age range 21-85 years
Exclusion Criteria:
- non-STEMI, STEMI
- cancer
- renal failure with creatinine>3.0mg/dl
- liver cirrhosis
- lymphoproliferative disorder
- pregnancy
- thrombocytopenia<150'000
- coagulopathy (INR>1.5)
- abnormal liver function tests
- illicit drug use
- history of statin intolerance
- history of rhabdomyolysis
- planned use of Glycoprotein IIb/IIIa inhibitors during PCI
- current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or
rosuvastatin
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials